INmune Bio
INMBINmune Bio is a clinical-stage biotechnology company focused on reprogramming the innate immune system to treat diseases driven by chronic inflammation and immune dysfunction.
Earnings
Next report
Oct 29, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
INmune Bio is a clinical-stage biotechnology company focused on reprogramming the innate immune system to treat diseases driven by chronic inflammation and immune dysfunction. The company develops proprietary platforms targeting neuroinflammation, oncology, and rare genetic disorders. Its core value proposition lies in delivering disease-modifying therapies for conditions with high unmet medical needs, such as Alzheimer's disease and Recessive Dystrophic Epidermolysis Bullosa.
A clinical-stage innovator in innate immune system reprogramming with multiple orphan drug and rare pediatric disease designations.
FAQ
- What is INmune Bio's market cap?
- INmune Bio (INMB) has a market capitalization of $67.9M and trades on NASDAQ.
- Who are INmune Bio's competitors?
- INmune Bio's key competitors include Biogen Inc., Eli Lilly and Company, Krystal Biotech, Inc., and others. These companies compete in similar markets and product categories.
- Who does INmune Bio partner with?
- INmune Bio's notable partners include Xencor, Inc., Great Ormond Street Hospital, University of Pittsburgh, and others.
- Where is INmune Bio headquartered?
- INmune Bio is headquartered in United States of America and employs approximately 17 people. It has been publicly traded since 2019.